A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

(2012) Vikas Sehdev et al.   CANCER

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

(2012) F J Giles et al.   LEUKEMIA

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic Myeloid Leukemia: State of the Art in 2012

(2012) Carmen Fava et al.   Current Oncology Reports

The potential role of Aurora kinase inhibitors in haematological malignancies

(2011) Sherif S. Farag   BRITISH JOURNAL OF HAEMATOLOGY

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Overcoming resistance in chronic myelogenous leukemia

(2010) Susannah Cooper et al.   LEUKEMIA & LYMPHOMA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents

(2009) John R. Pollard et al.   JOURNAL OF MEDICINAL CHEMISTRY